Efficacy
After 3 years of follow up the risk of recurrence was 27% (95% CI, 24 - 30) in the immediate and 36% (95% CI, 33-39) in the delayed instillation group (log-rank p <0.001). Time to recurrence is statistically significant in favour of the immediate instillation compared with delayed, with a 34% reduction in the relative risk of recurrence HR 0.66 (95% CI, 0.56 - 0.79, p < 0.001 multivariable). After total follow up the HR increased to 0.73 (95% CI, 0.63 - 0.85, p < 0.001, multivariable).r
Kaplan-Meier curve for probability of recurrence in the intention to treat populationr
© Euro Urol 2018
Recurrence risk per risk category after 3 years follow up in the intermediate and high risk groups and after 5 years of follow up in the low risk groupr
© Euro Urol 2018
A previous systematic review had demonstrated that a single immediate instillation was not of benefit in patients with a prior recurrence rate of more than one per year or an EORTC recurrence score equivalent to or greater than 5.r This was not the case in the re-analysis study, with a hazards ratio of 0.63 for patients with >1 recurrence per year, and a hazards ratio of 0.66 for patients with an EORTC score >5 (in favour of immediate instillation vs delayed).r
Effect of an immediate compared to a delayed instillation of mitomycin C on time to recurrence for multiple groupsr
© 2018 Uro Oncol